PepGen Inc. develops oligonucleotide therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 81 full-time employees. The company went IPO on 2022-05-06. The Company’s Enhanced Delivery Oligonucleotide (EDO) platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases. The company is focused on addressing the underlying cause of Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), which have high unmet need. Its pipeline consists of two clinical stage programs, PGN-EDO51 for DMD patients who are amenable to an exon 51-skipping approach and PGN-EDODM1 for DM1 patients, and several additional preclinical stage programs. Its product candidates also include PGN-EDO53, PGN-EDO45 and PGN-EDO44.
Follow-Up Questions
Qui est le CEO de PepGen Inc ?
Dr. James Mcarthur est le President de PepGen Inc, il a rejoint l'entreprise depuis 2021.
Quelle est la performance du prix de l'action PEPG ?
Le prix actuel de PEPG est de $2.15, il a increased de 5.12% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de PepGen Inc ?
PepGen Inc appartient à l'industrie Biotechnology et le secteur est Health Care
Quelle est la capitalisation boursière de PepGen Inc ?
La capitalisation boursière actuelle de PepGen Inc est de $70.6M
Est-ce que PepGen Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 8 analystes ont établi des notations d'analystes pour PepGen Inc, y compris 5 achat fort, 4 achat, 1 maintien, 1 vente et 5 vente forte
